Canada Fortifies Pandemic Defenses with Advanced Cell-Based Vaccine Deal

MONTREAL, QC – March 06, 2026 – The Canadian government has taken a significant step to reinforce its national pandemic defenses, finalizing a new agreement with global vaccine leader CSL Seqirus for millions of doses of a next-generation, cell-based influenza vaccine. The contract ensures a rapid supply for Canadians should the World Health Organization (WHO) declare an influenza pandemic, marking a pivotal technological upgrade from the nation's previous reliance on egg-based vaccine production.

The agreement with the Public Health Agency of Canada (PHAC) comes amid heightened global vigilance over the persistent spread of highly pathogenic avian influenza, underscoring the urgency of robust and rapid response capabilities. Under the terms, CSL Seqirus is committed to manufacturing and delivering an adjuvanted, cell-based vaccine from its state-of-the-art facility in Melbourne, Australia.

"This new contract with CSL Seqirus strengthens Canada's ability to respond quickly to a potential future flu pandemic," said the Honourable Marjorie Michel, Minister of Health, in a statement. "By securing access to millions of doses of flu vaccine if a pandemic is declared by the WHO, we are reinforcing our commitment to protecting health and being prepared and ready to act in the face of emerging public health threats."

A Technological Leap in Pandemic Defense

The shift from an egg-based to a cell-based vaccine platform represents a critical evolution in Canada's preparedness strategy. For decades, the standard method for producing flu vaccines involved growing candidate vaccine viruses in millions of chicken eggs—a time-consuming process vulnerable to supply chain disruptions and potential viral mutations.

Cell-based manufacturing bypasses these challenges. The technology uses cultured animal cells that can be frozen and stored in vast quantities, creating a "cell bank" ready for immediate use. This eliminates the need for a large and constant supply of specialized eggs, allowing vaccine production to begin almost instantly once a pandemic strain is identified. This speed is crucial in a pandemic scenario, where every day saved can translate into countless lives protected.

Beyond speed and scalability, cell-based technology offers the potential for a more effective vaccine. When influenza viruses are adapted to grow in eggs, they can undergo mutations that make them less like the circulating virus they are meant to target. Cell-based production avoids this "egg-adaptation," resulting in a vaccine virus that may be a closer antigenic match to the wild virus. Recent studies have reinforced these benefits, with some observational data suggesting that cell-based vaccines offer greater protection against flu-related hospitalizations and symptomatic illness compared to their egg-based counterparts.

This agreement builds on the successful integration of CSL Seqirus's seasonal cell-based vaccine, Flucelvax®, into Canada's public health programs over the past six years, providing a proven foundation for this pandemic-level commitment.

Bolstering a National Preparedness Strategy

This contract is a key component of Canada's broader, multi-layered pandemic preparedness framework, outlined in the Canadian Pandemic Influenza Preparedness (CPIP) plan. The strategy aims not only to secure vaccine supply but also to ensure its equitable and efficient distribution across the country. This latest agreement diversifies and modernizes the country's vaccine arsenal.

The federal government has maintained long-term contracts for pandemic vaccine supplies since 2001, learning critical lessons from past health crises, including the H1N1 pandemic and the recent COVID-19 pandemic. The CSL Seqirus deal complements other significant agreements, such as the one established with GSK in 2022. That contract secures up to 80 million doses of its adjuvanted pandemic vaccine, which is slated for production at its facility in Sainte-Foy, Quebec, further enhancing domestic response capabilities.

By securing access to different vaccine technologies from multiple global partners, Canada is building a more resilient and flexible defense system. "This new contract ensures Canada has guaranteed access to millions of vaccine doses and the capacity to respond quickly if a pandemic is declared," stated the Honourable Joel Lightbound, Minister of Government Transformation, Public Works and Procurement. "We're strengthening Canada's preparedness, reducing vulnerabilities in global supply chains, and making sure Canadians are protected when it matters most."

The Ever-Present Threat of Avian Influenza

The timing of the agreement is no coincidence. Public health agencies worldwide are on high alert due to the unprecedented spread of highly pathogenic avian influenza (HPAI) H5N1. The virus has caused mass mortality events in wild bird populations and has increasingly been detected in a wide range of mammal species, raising concerns about its potential to adapt for human-to-human transmission.

While the WHO currently assesses the public health risk as low, sporadic human cases continue to occur, often linked to close contact with infected animals. In November 2024, Canada confirmed its first-ever domestic human case of H5N1 in a teenager in British Columbia, a stark reminder that the virus is active within the country's borders. Although there is no evidence of sustained human-to-human spread, scientists warn that such a development could trigger a severe pandemic, given the population's lack of pre-existing immunity.

This looming threat highlights the necessity of the strategic partnership between governments and vaccine manufacturers. "A flu pandemic is an ever-present threat," said Gillian Stafford, Canadian Country Head Commercial Operations at CSL Seqirus. "If one strikes, our robust, rapid response capabilities will ensure all our Canadian counterparts have access to vaccines to help protect their populations. We're honoured to continue contracting with Canada, a leading country in pandemic preparedness, toward our shared goal of protecting public health."

The Global Race for Vaccine Superiority

Canada's investment in cell-based technology reflects a broader global trend. Governments and pharmaceutical companies are moving away from traditional production methods and pouring resources into more agile platforms capable of confronting rapidly evolving viral threats. The COVID-19 pandemic served as a powerful catalyst, demonstrating the game-changing potential of innovative platforms like mRNA.

The competitive landscape for pandemic influenza vaccines is now dominated by companies championing these advanced technologies. While CSL Seqirus and GSK are leaders with their cell-based and adjuvanted vaccines, other giants like Sanofi Pasteur, Pfizer, and Moderna are aggressively developing mRNA-based flu vaccines. These platforms promise even faster development and production timelines, turning the genetic sequence of a new virus into a deployable vaccine in record time.

This race for technological superiority is fundamentally reshaping global health security. By securing a robust supply of a proven, modern vaccine technology, Canada is ensuring it is not left behind. The agreement positions the nation to respond more effectively to the next influenza pandemic, leveraging scientific innovation to protect its citizens in an uncertain world.